CDD Overview

Welcome to the University of Georgia (UGA) Center for Drug Discovery (CDD). Your interest in the CDD is appreciated.

The Center was established to fulfill a state, national and international need for the discovery and development of new chemical and biological entities for combating a variety of existing and emerging life-threatening diseases for which the etiological agents are infectious viruses and infectious microbial agents. Signal transduction/cell signaling and disease states, cancer, stroke, Alzheimer's disease and disease targets are additional research areas of interest to the Center. The CDD brings together, in a collaborative spirit, scientists from different disciplines who are actively involved in various aspects of research associated with the discovery of therapeutic agents for a variety of serious diseases. The research disciplines covered include medicinal chemistry, chemical biology, biopharmaceutics, biochemistry, bioinformatics, cellular biology, structural biology, microbiology, virology, genetics, pharmacology, toxicology, proteomics and genomics, nanotechnology, cell and gene therapeutics and translational research.

The CDD contributes not only to the research and teaching mission and increased national stature of UGA, but also enhances research connections between UGA and other research institutions, government agencies and pharmaceutical companies at the regional, national and international levels.

In 2012, the CDD accepted the invitation of drug discovery scientists from Harvard, Johns Hopkins, UCSF, Vanderbilt and UNC to be part of the national Academic Drug Discovery Consortium (ADDC). The Director of the CDD also gave a presentation on the UGA CDD and its member research interests at the first national conference of the ADDC in 2013.

In 2015, Dr. Shelley Hooks was named Associate Director for the Center for Drug Discovery. Former Director of the Center, Dr. Vasu Nair, retired on July 31, 2015, and is now an Emeritus Associate Dean and Professor at UGA College of Pharmacy.

In 2018, Dr. Scott Pegan, Associate Professor, Department of Pharmaceutical and Biomedical Sciences,  became Interim Director of the Center.